{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:52:57Z","timestamp":1793987577126,"version":"4.8.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004433","name":"Chinese Pharmaceutical Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004433","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFF1205000"],"award-info":[{"award-number":["2023YFF1205000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.breast.2025.104550","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T22:25:14Z","timestamp":1754432714000},"page":"104550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Cost-effectiveness of sacituzumab tirumotecan versus chemotherapy for patients with metastatic triple-negative breast cancer in China"],"prefix":"10.1016","volume":"83","author":[{"given":"Yamin","family":"Shu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiling","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4779-3875","authenticated-orcid":false,"given":"Qilin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.breast.2025.104550_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.breast.2025.104550_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"2","key":"10.1016\/j.breast.2025.104550_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer - expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"25","key":"10.1016\/j.breast.2025.104550_bib5","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.2217\/fon-2018-0131","article-title":"Antibody-drug conjugates in triple negative breast cancer","volume":"14","author":"Tray","year":"2018","journal-title":"Future Oncol"},{"issue":"9","key":"10.1016\/j.breast.2025.104550_bib7","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","article-title":"Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.breast.2025.104550_bib8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/14737140.2019.1654378","article-title":"Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer","volume":"19","author":"Weiss","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"10.1016\/j.breast.2025.104550_bib9","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10549-020-05867-0","article-title":"Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine","volume":"184","author":"Kazmi","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2025.104550_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03630-w","article-title":"Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial","author":"Yin","year":"2025","journal-title":"Nat Med"},{"issue":"16","key":"10.1016\/j.breast.2025.104550_bib11","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.breast.2025.104550_bib13","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.clbc.2024.04.010","article-title":"Cost-effectiveness of sacituzumab govitecan versus single-agent chemotherapy for patients with metastatic triple-negative breast cancer in China","volume":"24","author":"Wang","year":"2024","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"10.1016\/j.breast.2025.104550_bib14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","article-title":"Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"issue":"12","key":"10.1016\/j.breast.2025.104550_bib15","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.jval.2020.08.2094","article-title":"Partitioned survival and state transition models for healthcare decision making in oncology: where are We Now?","volume":"23","author":"Woods","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.breast.2025.104550_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12962-019-0182-7","article-title":"A technique for approximating transition rates from published survival analyses","volume":"17","author":"Pahuta","year":"2019","journal-title":"Cost Eff Resour Alloc"},{"key":"10.1016\/j.breast.2025.104550_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"10.1016\/j.breast.2025.104550_bib18","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0272989X12472398","article-title":"Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide","volume":"33","author":"Latimer","year":"2013","journal-title":"Med Decis Mak"},{"issue":"12","key":"10.1016\/j.breast.2025.104550_bib19","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/s41416-018-0302-8","article-title":"Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint","volume":"119","author":"Rulli","year":"2018","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.breast.2025.104550_bib20","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40273-022-01227-6","article-title":"Cost-effectiveness analysis of a new second-line treatment regimen for advanced intrahepatic cholangiocarcinoma: biomarker-driven targeted therapy of Pemigatinib versus 5-FU chemotherapy","volume":"41","author":"Chueh","year":"2023","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.breast.2025.104550_bib21","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1177\/0272989X21992297","article-title":"Extrapolating parametric survival models in health technology assessment using model averaging: a simulation study","volume":"41","author":"Gallacher","year":"2021","journal-title":"Med Decis Mak"},{"issue":"1","key":"10.1016\/j.breast.2025.104550_bib22","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12911-024-02475-6","article-title":"SurvInt: a simple tool to obtain precise parametric survival extrapolations","volume":"24","author":"Gallacher","year":"2024","journal-title":"BMC Med Inform Decis Mak"},{"issue":"1","key":"10.1016\/j.breast.2025.104550_bib24","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12916-022-02516-9","article-title":"A cost-effectiveness analysis of capecitabine maintenance therapy versus routine follow-up for early-stage triple-negative breast cancer patients after standard treatment from a perspective of Chinese society","volume":"20","author":"Li","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.breast.2025.104550_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/17562848221140662","article-title":"First-line treatments for advanced hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis in China and the United States","volume":"15","author":"Sun","year":"2022","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.breast.2025.104550_bib27","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920916000","article-title":"Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer","volume":"12","author":"Wu","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"10.1016\/j.breast.2025.104550_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-094804","article-title":"Cost-effectiveness of atezolizumab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in the US and Chinese setting: a modelling comparison study","volume":"15","author":"Liu","year":"2025","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.breast.2025.104550_bib29","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.8065","article-title":"Nivolumab vs pembrolizumab for treatment of US patients with platinum-Refractory recurrent or metastatic head and Neck Squamous cell carcinoma: a network meta-analysis and cost-effectiveness analysis","volume":"4","author":"Pei","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.breast.2025.104550_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vhri.2020.07.580","article-title":"Current Development and practice of pharmacoeconomic evaluation guidelines for Universal health Coverage in China","volume":"24","author":"Yue","year":"2021","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.breast.2025.104550_bib31","series-title":"China guidelines for pharmacoeconomic evaluations 2020 (Chinese-English Version)","author":"Liu","year":"2020"},{"issue":"1","key":"10.1016\/j.breast.2025.104550_bib32","doi-asserted-by":"crossref","DOI":"10.1080\/20523211.2025.2464781","article-title":"Cost-effectiveness analysis of a first-line treatment with cadonilimab plus platinum-based chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer in China: COMPASSION-16 trial","volume":"18","author":"Ding","year":"2025","journal-title":"J Pharm Policy Pract"},{"issue":"3","key":"10.1016\/j.breast.2025.104550_bib33","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jval.2020.01.004","article-title":"Value of information Analytical methods: Report 2 of the ISPOR value of information analysis emerging Good practices Task force","volume":"23","author":"Rothery","year":"2020","journal-title":"Value Health"},{"issue":"12","key":"10.1016\/j.breast.2025.104550_bib35","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s40273-022-01196-w","article-title":"Cost effectiveness of adding pembrolizumab to platinum and Fluoropyrimidine-based chemotherapy as first-line treatment for advanced Esophageal cancer: a US healthcare Payer's perspective","volume":"40","author":"Qu","year":"2022","journal-title":"Pharmacoeconomics"},{"issue":"15","key":"10.1016\/j.breast.2025.104550_bib36","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1200\/JCO.23.01409","article-title":"Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression","volume":"42","author":"Bardia","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.breast.2025.104550_bib37","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","article-title":"Gemtuzumab ozogamicin versus best supportive Care in older patients with Newly diagnosed acute myeloid leukemia Unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial","volume":"34","author":"Amadori","year":"2016","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.breast.2025.104550_bib38","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"issue":"9825","key":"10.1016\/j.breast.2025.104550_bib39","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2025.104550_bib40","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.breast.2023.02.003","article-title":"Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer","volume":"68","author":"Lang","year":"2023","journal-title":"Breast"},{"issue":"2","key":"10.1016\/j.breast.2025.104550_bib41","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/14737167.2023.2291155","article-title":"Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore","volume":"24","author":"Cher","year":"2024","journal-title":"Expert Rev Pharmacoecon Outcomes Res"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625005673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625005673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T09:49:22Z","timestamp":1772790562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977625005673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":35,"alternative-id":["S0960977625005673"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2025.104550","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of sacituzumab tirumotecan versus chemotherapy for patients with metastatic triple-negative breast cancer in China","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2025.104550","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104550"}}